Publications (original articles or review articles) published in 2015 from OUS - Department of Gynaecological Oncology
13 publications found
Intra-Gene DNA Methylation Variability Is a Clinically Independent Prognostic Marker in Women's Cancers
PLoS One, 10 (12), e0143178
DOI 10.1371/journal.pone.0143178, PubMed 26629914
Psychological distress related to BRCA testing in ovarian cancer patients
Fam Cancer, 14 (4), 495-504
DOI 10.1007/s10689-015-9811-2, PubMed 25980896
HUR mRNA expression in ovarian high-grade serous carcinoma effusions is associated with poor survival
Hum Pathol, 48, 95-101
DOI 10.1016/j.humpath.2015.09.027, PubMed 26640230
Standard first-line chemotherapy with or without nintedanib for advanced ovarian cancer (AGO-OVAR 12): a randomised, double-blind, placebo-controlled phase 3 trial
Lancet Oncol, 17 (1), 78-89
DOI 10.1016/S1470-2045(15)00366-6, PubMed 26590673
MicroRNAs in Ovarian Cancer
Hum Pathol, 46 (9), 1245-56
DOI 10.1016/j.humpath.2015.06.013, PubMed 26216350
Interplay between promoter methylation and chromosomal loss in gene silencing at 3p11-p14 in cervical cancer
Epigenetics, 10 (10), 970-80
DOI 10.1080/15592294.2015.1085140, PubMed 26291246
Body mass index, diabetes and survival after diagnosis of endometrial cancer: A report from the HUNT-Survey
Gynecol Oncol, 139 (3), 476-80
DOI 10.1016/j.ygyno.2015.09.088, PubMed 26434365
The impact of cisplatinum-based chemotherapy on ventricular function and cardiovascular risk factors in female survivors after malignant germ cell cancer
ESC Heart Fail, 2 (3), 142-149
DOI 10.1002/ehf2.12048, PubMed 28834675
Expression and clinical role of chemoresponse-associated genes in ovarian serous carcinoma
Gynecol Oncol, 139 (1), 30-9
DOI 10.1016/j.ygyno.2015.07.107, PubMed 26232338
CIAPIN1 and ABCA13 are markers of poor survival in metastatic ovarian serous carcinoma
Mol Cancer, 14, 44
DOI 10.1186/s12943-015-0317-1, PubMed 25889687
Standard chemotherapy with or without bevacizumab for women with newly diagnosed ovarian cancer (ICON7): overall survival results of a phase 3 randomised trial
Lancet Oncol, 16 (8), 928-36
DOI 10.1016/S1470-2045(15)00086-8, PubMed 26115797
Alopecia as surrogate marker for chemotherapy response in patients with primary epithelial ovarian cancer: a metaanalysis of four prospective randomised phase III trials with 5114 patients
Eur J Cancer, 51 (7), 825-32
DOI 10.1016/j.ejca.2015.01.008, PubMed 25771433
HOTAIR and its surrogate DNA methylation signature indicate carboplatin resistance in ovarian cancer
Genome Med, 7, 108
DOI 10.1186/s13073-015-0233-4, PubMed 26497652